查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931245

植入式藥物洗脫支架市場（按支架代數、聚合物塗層、藥物塗層和最終用戶分類），全球預測，2026-2032年

Implantable Drug Eluting Stent Market by Stent Generation, Polymer Coating, Drug Coating, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年植入式藥物釋放型支架市值為37.7億美元，預計到2026年將達到40.5億美元，年複合成長率為8.53%，到2032年將達到66.9億美元。

關鍵市場統計數據
基準年 2025 37.7億美元
預計年份：2026年 40.5億美元
預測年份 2032 66.9億美元
複合年成長率 (%) 8.53%

建構臨床、商業性和監管環境框架，以塑造植入式藥物釋放型支架生態系統中的創新應用和策略重點。

植入式藥物釋放型支架市場處於醫療創新、監管審查和醫療服務模式變革的交匯點。本報告首先界定了醫療設備製造商、醫院系統和專業經銷商所處的臨床和商業性環境。報告揭示了治療重點——改善血管癒合、減少血管再阻塞和最大限度地降低晚期血栓事件——如何推動器械設計和藥物塗層的持續改進，並說明了報銷壓力和採購慣例如何影響臨床實踐中的應用曲線。

檢驗融合的技術、臨床和分銷變革，這些變革將重新定義競爭優勢並推動下一代藥物釋放型支架的普及應用。

過去五年發生了翻天覆地的變化，重塑了植入式藥物釋放型支架的競爭優勢，並影響採購決策。聚合物技術的進步加速了從耐用塗層向生物可吸收、無聚合物設計的轉變，改變了介入性心臟病專家的風險獲益評估，並促使開展了以長期血管癒合為重點的新臨床試驗。同時，藥物塗層的發展也超越了傳統藥物；雖然Everolimus和Sirolimus仍然是基礎藥物，但藥物釋放曲線的選擇性最佳化和新型輔料的引入，創造了差異化的性能屬性，並促成了直接對比試驗的開展。

評估2025年關稅調整和貿易政策轉變如何重塑支架製造商和供應商的採購、成本結構和供應鏈韌性。

美國2025年實施的關稅和貿易政策調整，為植入式藥物釋放型支架全球供應鏈的營運企業帶來了更多複雜性。某些醫療設備組件和上游原料關稅的提高，增加了從國際供應商採購聚合物樹脂、特殊金屬和某些活性藥物成分的製造商的投入成本。為此，醫療設備製造商正在重新審視其籌資策略，加快對替代供應商的資格認證，並調整庫存政策，以確保供應的連續性，同時控制利潤壓力。

深入的細分分析，將終端用戶需求、設備世代、聚合物策略、藥物包衣和分銷管道與商業性和臨床優先事項相匹配。

細分市場分析揭示了臨床、營運和商業性動態的交匯點，這些因素會影響產品定位和通路策略。按最終用戶分類，市場細分為門診手術中心、心臟導管介入檢查室和醫院。心臟導管介入檢查室進一步細分為檢查室實驗室和公共檢查室。醫院進一步細分為私立醫院和公立醫院。這些最終用戶的區別至關重要：門診機構優先考慮的是吞吐量、簡化的庫存管理和設備的易用性，而醫院系統則重視廣泛的臨床適應性、長期療效數據以及能夠兼顧住院和門診病人收入的整合採購流程。

區域趨勢和醫療保健系統差異將影響全球市場的證據要求、分發策略和採納路徑

區域趨勢對生物可吸收藥物釋放型支架的監管時間表、臨床實踐模式和分銷模式有顯著影響。在美洲地區，激烈的醫保報銷談判、三級醫療中心的高手術量以及擇期手術日益轉移到門診的趨勢，正在塑造該地區的商業環境。這些因素促使市場對能夠提供可預測的臨床結果、簡化的庫存管理以及強力的上市後證據以支持合約決策的醫療器材的需求不斷成長。

競爭行動和企業策略優先考慮臨床差異化、生產彈性和證據生成，以確保長期市場地位。

植入式藥物釋放型支架領域的企業競爭格局反映了技術能力、臨床證據、生產規模和通路執行力之間的平衡。成熟的跨國公司往往憑藉其廣泛的臨床試驗項目、整合的銷售團隊和全球製造地，在關鍵地區保持領先地位。同時，新興企業則專注於材料科學創新、特定患者群體或成本效益高的生產方式，試圖佔據特定細分市場。

為製造商和相關人員提供切實可行的策略措施，以加強其證據策略、保障供應鏈安全並最佳化混合上市策略。

為了駕馭不斷變化的藥物釋放型支架市場，產業領導者應協調產品開發、臨床證據產生和商業化，以降低市場進入門檻並提升長期價值。應優先考慮將材料和藥物創新與切實可行的臨床試驗設計相結合的開發路徑，從而產生符合監管要求的結果以及適用於與支付方討​​論的真實世界證據。這種雙重證據方法將透過展示療效和實用性來加速醫院系統的核准流程，並有助於合約談判。

採用嚴謹的混合方法研究策略，結合與臨床相關人員的直接溝通、二手文獻綜合分析和分析建模，以得出可操作且有效的研究結果。

本研究採用混合方法，結合與主要相關人員的直接對話、二手資料綜合和分析建模，以確保獲得全面且可靠的見解。主要研究包括對介入性心臟病專家、醫院和門診中心的採購人員、監管事務專業人員以及分銷合作夥伴進行結構化訪談，以了解他們對臨床優先事項、採購行為和物流限制的細緻觀點。這些訪談旨在探討聚合物策略、藥物包覆和器材迭代在實際決策中的相對重要性。

將創新轉化為持續的臨床應用和強大的商業性優勢的關鍵趨勢和策略原則的綜合分析

總之，植入式藥物釋放型支架市場正隨著材料科學、藥物傳遞技術和商業化模式的同步創新而不斷發展。臨床需求日益集中在那些不僅手術操作簡便，而且能夠促進血管長期癒合並最大限度降低併發症風險的器械。同時，分銷通路的複雜性和近期的貿易趨勢要求製造商在提高全球採購效率、實現在地化生產和建立穩健的物流系統之間取得平衡。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依支架代別植入式藥物洗脫支架市場

  • 第一代
  • 第二代
  • 第三代

第9章 依聚合物塗層分類的植入式藥物洗脫支架市場

  • 生物可吸收聚合物
    • 聚左旋乳酸
    • 聚乙醇酸
  • 耐用聚合物
  • 不含聚合物

第10章 依藥物塗層分類的植入式藥物洗脫支架市場

  • Everolimus
  • 紫杉醇
  • Sirolimus
  • 佐他羅莫司

第11章植入式藥物洗脫支架市場（依最終用戶分類）

  • 門診手術中心
  • 心臟導管檢查室
  • 醫院
    • 私立醫院
    • 公立醫院

第12章植入式藥物洗脫支架市場（依地區分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章植入式藥物洗脫支架市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國植入式藥物洗脫支架市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國植入式藥物洗脫支架市場

第16章：中國植入式藥物洗脫支架市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alvimedica Medical Technologies Inc.
  • B. Braun Melsungen AG
  • Balton Sp. z oo
  • Biosensors International Group, Ltd.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Concept Medical, Inc.
  • Cook Medical Incorporated
  • Elixir Medical Corporation
  • Eucatech AG
  • Eurocor GmbH
  • iVascular SLU
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medinol Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • OrbusNeich Medical Group
  • Sahajanand Medical Technologies Ltd.
  • Terumo Corporation
Product Code: MRR-7B550E008DE1

The Implantable Drug Eluting Stent Market was valued at USD 3.77 billion in 2025 and is projected to grow to USD 4.05 billion in 2026, with a CAGR of 8.53%, reaching USD 6.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.77 billion
Estimated Year [2026] USD 4.05 billion
Forecast Year [2032] USD 6.69 billion
CAGR (%) 8.53%

Framing the clinical, commercial, and regulatory context that shapes innovation adoption and strategic priorities across the implantable drug eluting stent ecosystem

The implantable drug eluting stent market sits at the intersection of medical innovation, regulatory scrutiny, and shifting care delivery models. This report begins by framing the clinical and commercial context in which device manufacturers, hospital systems, and specialty distributors operate. It clarifies how therapeutic priorities-improving vascular healing, reducing restenosis, and minimizing late thrombotic events-drive continuous iteration in device design and pharmacologic coatings, while reimbursement pressures and procurement practices influence adoption curves across care settings.

From a clinical perspective, physicians increasingly favor technologies that balance deliverability, acute performance, and long-term vessel integrity. Emerging polymer strategies and novel antiproliferative agents aim to shorten recovery windows and mitigate adverse events, prompting hospitals and catheterization laboratories to reassess procurement criteria. Concurrently, payers and health systems place more emphasis on health-economic outcomes and real-world evidence to justify premium pricing and to support pathway integration.

Commercially, competitive dynamics are shaped by a small number of established multinational firms and a growing cohort of specialized entrants focused on polymer science and drug chemistry. This landscape fosters both consolidation and targeted partnership strategies between device makers and contract manufacturers. Taken together, the introduction sets expectations for a market where clinical efficacy, regulatory compliance, supply chain resilience, and channel sophistication jointly determine which innovations achieve durable clinical and commercial success.

Examining the converging technological, clinical, and distribution shifts that redefine competitive advantage and drive adoption of next-generation drug eluting stents

The past five years have seen transformative shifts that reconfigure competitive advantage and influence procurement decisions for implantable drug eluting stents. Advances in polymer technology have accelerated the transition from durable coatings to bioabsorbable and polymer-free designs, altering the risk-benefit calculus for interventional cardiologists and prompting new clinical trials focused on long-term vessel healing. Simultaneously, drug coating evolution has expanded beyond traditional agents; while Everolimus and Sirolimus remain foundational, selective optimization of drug-release profiles and novel excipients are creating differentiated performance characteristics that invite head-to-head comparative studies.

Care delivery transformation is another critical axis of change. Cardiac procedures are increasingly decentralized, with ambulatory surgery centers and private catheterization laboratories performing a growing share of elective interventions. This trend reshapes service expectations, procurement timelines, and stock management practices, while driving demand for stents that balance ease of handling with broad compatibility across imaging and interventional systems. Regulatory environments have also matured, placing greater emphasis on post-market surveillance and real-world evidence, which in turn incentivizes manufacturers to invest in longitudinal registries and digital follow-up solutions.

Finally, strategic partnerships and commercialization models have diversified. Manufacturers are experimenting with hybrid distribution, combining direct sales with specialized distributor arrangements and OEM partnerships to reach niche customer segments efficiently. The net effect of these transformative shifts is a market that rewards integrated clinical data, nimble supply chains, and product architectures designed for both immediate procedural performance and favorable long-term outcomes.

Assessing how 2025 tariff adjustments and trade policy shifts have reshaped sourcing, cost structures, and supply chain resilience for stent manufacturers and providers

Recent tariff actions and trade policy adjustments in the United States during 2025 introduced additional complexity for companies operating global supply chains for implantable drug eluting stents. Tariff increases on selected medical device components and upstream materials elevated input costs for manufacturers that source polymer resins, specialty metals, and certain active pharmaceutical ingredients from international suppliers. In response, device makers have revisited sourcing strategies, accelerated qualification of alternative suppliers, and adjusted inventory policies to preserve continuity of supply while managing margin pressure.

Beyond direct cost implications, the tariffs have had broader operational ripple effects. Companies with vertically integrated manufacturing that previously optimized global cost arbitrage faced renewed incentives to localize certain production stages to mitigate customs-related delays and duties. Contract manufacturers serving multiple OEMs experienced mixed impacts depending on their footprint and pass-through pricing power, prompting re-negotiations of long-term service agreements and lead-time commitments.

Clinicians and hospital procurement teams observed these shifts through changes in product availability, list prices, and contract terms. Some health systems prioritized multi-supplier strategies and framework agreements to insulate clinical programs from single-vendor disruptions. Moving forward, the cumulative impact of tariff changes underscores the need for scenario-based planning that incorporates customs risk, supplier redundancy, and cost-to-serve analysis when assessing new product introductions or portfolio expansions.

Detailed segmentation insights that align end-user needs, device generations, polymer strategies, drug coatings, and distribution channels to commercial and clinical priorities

Segmentation analysis reveals where clinical, operational, and commercial dynamics intersect to influence product positioning and channel strategy. Based on End User, market is studied across Ambulatory Surgery Centers, Cardiac Catheterization Laboratories, and Hospitals. The Cardiac Catheterization Laboratories is further studied across Private Laboratories and Public Laboratories. The Hospitals is further studied across Private Hospitals and Public Hospitals. These end-user distinctions are consequential: ambulatory settings prioritize throughput, simplified inventory, and device ease-of-use, while hospital systems emphasize broad clinical versatility, long-term outcomes data, and integrated purchasing processes that reflect inpatient and outpatient revenue considerations.

Product lifecycle and clinical differentiation also hinge on Stent Generation, market is studied across First Generation, Second Generation, and Third Generation. First generation devices established foundational antiproliferative approaches but faced limitations tied to durable polymer biocompatibility. Second generation iterations improved deliverability and drug kinetics, while third generation platforms emphasize bioabsorbable elements, thinner strut designs, and refined drug-release profiles, targeting improved vascular healing and lower long-term complication rates. These evolutionary steps create distinct value propositions that influence clinician preference and formulary inclusion.

Material science and polymer strategy carry further implications for regulatory pathways and clinician acceptance. Based on Polymer Coating, market is studied across Bioabsorbable Polymer, Durable Polymer, and Polymer Free. The Bioabsorbable Polymer is further studied across Poly-L-Lactic Acid and Polyglycolic Acid. Devices built on bioabsorbable polymers may reduce chronic inflammation and late adverse events, but they require robust long-term evidence and meticulous manufacturing controls. Durable polymer platforms remain attractive for proven performance and predictable drug release, whereas polymer-free designs aim to minimize foreign-body exposure, offering differentiated risk profiles that can appeal to specific patient cohorts.

Pharmacologic selection also materially affects clinical use and competitive messaging. Based on Drug Coating, market is studied across Everolimus, Paclitaxel, Sirolimus, and Zotarolimus. Each agent brings unique pharmacodynamics and clinical legacy, influencing physician preference and trial design. Finally, distribution strategy shapes market access pathways. Based on Distribution Channel, market is studied across Direct Sales and Distributors. The Direct Sales is further studied across In-House and Oem Partnerships. The Distributors is further studied across Medical Device Wholesalers and Specialty Distributors. Direct sales models enable tighter clinical engagement and integrated training programs, while distributor networks provide reach, logistical support, and localized regulatory know-how. Taken together, these segmentation lenses provide a structured way to align product development, evidence generation, and go-to-market models with end-user priorities and clinical expectations.

Regional dynamics and healthcare system variations that determine evidence requirements, distribution strategies, and adoption pathways across global markets

Regional dynamics exert a powerful influence on regulatory timelines, clinical practice patterns, and distribution models for implantable drug eluting stents. In the Americas, commercial environments are shaped by competitive reimbursement negotiations, high procedural volumes in tertiary centers, and a growing trend of moving elective interventions toward ambulatory settings. These forces create a demand for devices that offer predictable clinical outcomes, streamlined inventory management, and strong post-market evidence to justify contracting decisions.

In Europe, Middle East & Africa, heterogeneity defines strategy. Regulatory harmonization efforts coexist with widely varying payer structures and hospital capabilities, from large academic centers in metropolitan hubs to smaller public hospitals and private clinics. Local procurement authorities often require region-specific clinical data or value dossiers, pushing manufacturers to design flexible evidence generation programs. Supply chain complexity in the region also makes distributor partnerships valuable for navigating customs, logistics, and service requirements.

Asia-Pacific combines rapid adoption of minimally invasive technologies with diverse regulatory pathways and manufacturing capabilities. High-volume centers in certain markets accelerate uptake of new stent generations, while cost-sensitive systems in other countries prioritize durable performance and procurement efficiency. Across all regions, demographic trends such as aging populations and rising cardiovascular disease prevalence sustain clinical demand, but regional variations in procedure settings and payer expectations necessitate bespoke commercialization strategies that reconcile global product standards with localized clinical and economic requirements.

Competitive behaviours and corporate strategies that prioritize clinical differentiation, manufacturing agility, and evidence generation to secure long-term positioning

Competitive positioning among companies in the implantable drug eluting stent arena reflects a balance of technological capabilities, clinical evidence, manufacturing scale, and channel execution. Established multinational firms frequently leverage broad clinical trial programs, integrated sales forces, and global manufacturing footprints to maintain leadership in core geographies, while specialized challengers concentrate on material science innovations, niche patient cohorts, or cost-efficient manufacturing to capture targeted segments.

Strategic behaviors observed across leading companies include investment in longitudinal registries, cross-functional collaborations with interventional cardiology opinion leaders, and selective vertical integration to manage key material inputs. Some firms prioritize strengthening OEM partnerships and contract manufacturing relationships to enhance production flexibility, whereas others focus on direct sales channels to preserve clinical engagement and margins. Portfolio rationalization is also evident: products with differentiated clinical profiles and compelling operational advantages receive prioritized development budgets, while legacy platforms are managed through life-cycle support and selective geographic withdrawals.

Mergers and acquisitions remain a tactical avenue to access manufacturing technologies, complementary product lines, or regulatory filings. Companies also increasingly adopt modular commercialization approaches that combine in-house clinical affairs teams with external data-services partners to accelerate real-world evidence generation. Collectively, these corporate strategies reveal a market that rewards clarity of clinical differentiation, supply-chain robustness, and the ability to translate technical innovation into demonstrable patient and system-level outcomes.

Actionable strategic moves for manufacturers and stakeholders to strengthen evidence strategies, secure supply chains, and optimize hybrid go-to-market approaches

To navigate the evolving implantable drug eluting stent landscape, industry leaders should align product development, clinical evidence generation, and commercialization to reduce adoption friction and enhance long-term value. Prioritize development pathways that couple material and drug innovations with pragmatic clinical trial designs that produce both regulatory-grade outcomes and real-world evidence suitable for payer engagement. This dual evidence approach accelerates credentialing with hospital systems and supports contracting discussions by demonstrating both efficacy and practical utility.

Supply-chain resilience is equally critical. Implement supplier diversification plans and qualify alternative material sources for polymer resins, specialty metals, and active pharmaceutical components to mitigate customs and tariff exposure. Consider nearshoring or regional manufacturing nodes to shorten lead times and reduce exposure to cross-border tariffs and logistical disruptions. Operationally, invest in demand-sensing capabilities that align production with procedural seasonality and evolving care-site mixes.

Commercial models should blend direct engagement where clinical complexity demands hands-on training with distributor relationships that enable reach into fragmented markets and resource-constrained institutions. Finally, foster clinician partnerships early to drive adoption pathways: co-develop training curricula, support longitudinal outcomes tracking, and facilitate peer-to-peer dissemination of best practices. Such integrated strategies position organizations to translate technical advances into sustained clinical uptake and commercial performance.

A rigorous mixed-methods research approach combining primary clinical engagement, secondary literature synthesis, and analytical modeling to produce actionable and defensible insights

This research applies a mixed-methods approach that blends primary stakeholder engagement with secondary data synthesis and analytical modeling to ensure comprehensive and defensible insights. Primary research included structured interviews with interventional cardiologists, procurement leaders across hospitals and ambulatory centers, regulatory affairs specialists, and distribution partners to capture nuanced perspectives on clinical priorities, purchasing behavior, and logistical constraints. These conversations were designed to probe the relative importance of polymer strategies, drug coatings, and device generations in real-world decision-making.

Secondary data inputs consisted of peer-reviewed clinical literature, regulatory filings, public clinical registry outputs, and company disclosures to contextualize primary findings and validate technical assertions. Data validation processes included triangulation across sources, cross-verification with clinical experts, and assessment of evidence quality to ensure recommendations rest on robust signals rather than isolated datapoints. The methodology places particular emphasis on longitudinal outcomes evidence and post-market performance metrics as key indicators of sustainable device value.

Analytical techniques incorporated segmentation mapping, scenario analysis for supply-chain exposures, and vendor capability assessments to translate qualitative insights into operationally relevant conclusions. Ethical safeguards and confidentiality protocols were observed during primary research to protect respondent anonymity and to promote candid participation. The methodology is therefore designed to support strategic decision-making by combining practitioner insight, technical literature, and pragmatic operational analysis.

Synthesis of key trends and strategic principles that convert technical innovation into durable clinical adoption and resilient commercial advantage

In conclusion, the implantable drug eluting stent market is advancing through parallel innovations in materials science, pharmacologic delivery, and commercialization models. Clinical demand increasingly favors devices that demonstrate not only procedural excellence but also favorable long-term vessel healing and minimized complication risk. At the same time, distribution complexities and recent trade dynamics require manufacturers to carefully balance global sourcing efficiencies with localized production and resilient logistics.

Strategic success will hinge on an integrated approach that connects technical differentiation with pragmatic evidence generation, supply-chain robustness, and hybrid go-to-market strategies tailored to end-user needs. Manufacturers that invest in diversified polymer platforms, targeted drug-release technologies, and comprehensive real-world outcomes programs will be better positioned to secure formulary acceptance and clinician preference across hospitals, private and public catheterization laboratories, and ambulatory surgery centers. Regional nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific underscore the importance of bespoke commercialization plans that reconcile global product standards with local regulatory and payer environments.

Ultimately, the most successful organizations will be those that convert innovation into demonstrable clinical and operational benefits while sustaining agility in sourcing and distribution. This balanced focus will enable them to respond to shifting care settings and policy environments while preserving the confidence of clinicians, payers, and patients alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Drug Eluting Stent Market, by Stent Generation

  • 8.1. First Generation
  • 8.2. Second Generation
  • 8.3. Third Generation

9. Implantable Drug Eluting Stent Market, by Polymer Coating

  • 9.1. Bioabsorbable Polymer
    • 9.1.1. Poly-L-Lactic Acid
    • 9.1.2. Polyglycolic Acid
  • 9.2. Durable Polymer
  • 9.3. Polymer Free

10. Implantable Drug Eluting Stent Market, by Drug Coating

  • 10.1. Everolimus
  • 10.2. Paclitaxel
  • 10.3. Sirolimus
  • 10.4. Zotarolimus

11. Implantable Drug Eluting Stent Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Cardiac Catheterization Laboratories
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Implantable Drug Eluting Stent Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Implantable Drug Eluting Stent Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Implantable Drug Eluting Stent Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Implantable Drug Eluting Stent Market

16. China Implantable Drug Eluting Stent Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alvimedica Medical Technologies Inc.
  • 17.7. B. Braun Melsungen AG
  • 17.8. Balton Sp. z o.o.
  • 17.9. Biosensors International Group, Ltd.
  • 17.10. BIOTRONIK SE & Co. KG
  • 17.11. Boston Scientific Corporation
  • 17.12. Concept Medical, Inc.
  • 17.13. Cook Medical Incorporated
  • 17.14. Elixir Medical Corporation
  • 17.15. Eucatech AG
  • 17.16. Eurocor GmbH
  • 17.17. iVascular S.L.U.
  • 17.18. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.19. Medinol Ltd.
  • 17.20. Medtronic plc
  • 17.21. Meril Life Sciences Pvt. Ltd.
  • 17.22. OrbusNeich Medical Group
  • 17.23. Sahajanand Medical Technologies Ltd.
  • 17.24. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLY-L-LACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLY-L-LACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLY-L-LACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYGLYCOLIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYGLYCOLIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYGLYCOLIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 127. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 128. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 129. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 148. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 149. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 150. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 155. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 156. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 157. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)